Latest news with #MoolecScience
Associated Press
7 hours ago
- Business
- Associated Press
Moolec Science Secures Core U.S. Patent for Piggy Sooy(TM), Soybean Expressing Up to 30% of Animal Protein
WARWICK, GB / ACCESS Newswire / June 18, 2025 / Moolec Science Limited a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC; 'The Company"; 'Moolec'), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its proprietary groundbreaking Piggy Sooy™ technology - soybean plant engineered to express high levels of porcine hemeproteins in their Science Logo Piggy Sooy™ is the first patented soybean technology designed to produce high levels of porcine hemeproteins directly in the seeds. The U.S. patent covers the plants and seeds, the method used to develop them, and food compositions derived from this breakthrough innovation. In April 2024, the USDA-APHIS confirmed that Piggy Sooy™ does not present plant pest risk difference from conventional soybeans, determining it is not subject to regulation under 7 CFR part 340 - a key regulatory milestone toward commercialization. Moolec's Chief Science Officer, Amit Dhingra, stated: 'Initial field trials demonstrated promising production yield, with over 20% animal protein content in the total soluble protein fraction. Furthermore, the deployment of Piggy Sooy™ technology presents compelling environmental benefits when compared to traditional agricultural and meat production practices. One acre of Piggy Sooy™ has the potential capacity to produce the same amount of protein as approximately 10 pigs, using ~35x less land, generating ~8x less water footprint and ~60x less CO2 emissions. These multifaceted benefits make Piggy Sooy™ a game-changer in sustainable protein production.' This patent provides Moolec with exclusive commercial rights to Piggy Sooy™ technology in the U.S. until 2042, significantly strengthening the Company's intellectual property portfolio. This is the first in a series of over fifteen patent applications filed globally aimed at protecting Moolec's Molecular Farming innovations. 'Our experience has taught us that long-term success in biotechnology is built on securing robust, enforceable intellectual property. This patent validates Moolec's scientific leadership in Molecular Farming and protects a technology with unprecedented levels of animal protein expression in plants. It's not only a recognition of our innovation, but a vital asset that allows us to advance confidently toward commercialization and build a differentiated position in our food and feed ingredients business,' said Alejandro Antalich, CEO of Moolec Science. Contact InformationPress & Media Investor Relations SOURCE: Moolec Science press release
Yahoo
a day ago
- Business
- Yahoo
Moolec Science Announces Successful Closing of Business Combination, Expanding Across Life Sciences and Food-Tech
GRAND CAYMAN, CAYMAN ISLANDS / / June 17, 2025 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced the successful closing of its previously announced strategic business combination (the "Business Combination") with Bioceres Group Limited ("Bioceres Group"), Gentle Technologies Corp ("Gentle Tech"), and Nutrecon LLC ("Nutrecon"). With the closing, Moolec emerges as the parent company of a significantly expanded and enhanced enterprise at the forefront of sustainable life sciences and food-tech innovation. This transformative transaction brings together complementary capabilities across food ingredients, ag-biologicals, precision fermentation, biomaterials, and R&D services, consolidating Moolec's position as a differentiated life science platform focused on sustainable solutions from molecule to ingredient. The Business Combination, initially announced on April 17, 2025, was ratified by Moolec shareholders at the Extraordinary General Meeting ("EGM") held on June 16, with ~77% of the outstanding shares present at the meeting, and ~98% of the votes cast were in favor of the transaction. Under the terms of the transaction, Bioceres Group shareholders have exchanged their equity ownership for approximately 6.9 million shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech have received, in exchange for their ownership in these entities, approximately 0.65 million shares of Moolec and 0.5 million Moolec private warrants, each with a strike price of $20.00. The combined company will continue operating under the name Moolec Science, with its securities trading on NASDAQ under the ticker symbols "MLEC" and "MLECW". The Board of Directors has appointed Mr. Alejandro Antalich as Chief Executive Officer of Moolec Science. Mr. Antalich brings over 20 years of international leadership experience in biotechnology and life sciences, with a proven track record of scaling sustainable technologies, driving strategic partnerships, M&A, and delivering significant growth through value-creating transactions. Prior to this appointment, he served as CEO of Nutrecon, where he positioned the company as a key innovator in precision fermentation and alternative protein ingredients, and established a state-of-the-art synthetic biology platform providing integrated R&D, contract development, and manufacturing services. Earlier in his career, he led an innovative life sciences company, guiding its international expansion and executing its strategic sale to a global publicly traded corporation in a landmark transaction valued at nearly $300 million. Key highlights: Ingredient Innovation: Moolec will continue advancing its flagship molecular farming products, such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ - acquired through Nutrecon - under the Eternal® brand to expand its alternative protein offering. Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-smart seeds under the Rizobacter®, ProFarm®, and HB4® brands. Integrated R&D and Technical Capabilities: With cutting-edge infrastructure through Agrality® and Synbio Powerlabs® - platforms belonging to Bioceres Group and Nutrecon, respectively - Moolec now benefits from in-house R&D, CDMO and regulatory capabilities designed to accelerate the development, testing, and regulatory progression of its technology pipeline. Emerging Tech & Equipment: The Company will also expand its presence in emerging technologies for grain and biomass transformation, particularly within the biomaterials space, as well as new concepts in farm equipment that integrate material science, electric mobility, and autonomy. These initiatives are currently being developed through subsidiaries of Gentle Tech and Bioceres Group. Forward Looking Statements This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements. Contact Information Press & Media comms@ Investor Relations ir@ SOURCE: Moolec Science SA View the original press release on ACCESS Newswire
Business Insider
14-05-2025
- Business
- Business Insider
Moolec Science SA trading halted, news pending
19:50 EDT Moolec Science (MLEC) SA trading halted, news pending Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Associated Press
12-05-2025
- Business
- Associated Press
Moolec Science Announces Effectiveness of Reverse Stock Split
LUXEMBOURG, LU / ACCESS Newswire / May 12, 2025 / Moolec Science SA (NASDAQ:MLEC; the 'Company' or 'Moolec'), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that, in accordance with the resolutions passed at the extraordinary general meeting of shareholders held on April 22, 2025, and the resolutions adopted by the Company's board of directors on the same date, the Company has approved a reverse stock split at a consolidation ratio of one-for-ten (1-for-10). As a result, every ten ordinary shares of the Company, with a par value of US$0.01 per share (the 'Shares'), issued and outstanding will automatically, and without any action required on the part of the holders, be consolidated into one validly issued, fully paid, and non-assessable Share, with no change to the par value per share (the 'Reverse Stock Split').Moolec Science Logo The Company anticipates that the Reverse Stock Split will take effect May 14, 2025, 8:30 AM Eastern Time (the 'Effective Time') and will be reflected in the market at the start of trading, on a split-adjusted basis. The Shares will continue to trade on the NASDAQ under the symbol 'MLEC' under a new CUSIP code, which is L64875 120. The Company's publicly traded warrants will continue to be traded under the symbol 'MLECW' under the same CUSIP code, which is L64875 112. As a result of the Reverse Stock Split the number of issued and outstanding Shares will be reduced from approximately 40 million Shares to approximately 4 million Shares. The Reverse Stock Split does not otherwise affect the Company's business or operations. Registered shareholders are not required to take any action to receive Shares in connection with the Reverse Stock Split. Shareholders owning shares through an account at a brokerage firm, bank, dealer, custodian or other similar organization acting as nominee will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to such broker's particular processes, and likewise will not be required to take any action in connection with the Reverse Stock Split. Forward Looking Statements This press release contains 'forward-looking statements.' Forward-looking statements may be identified by the use of words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' 'outlook,' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header 'Risk Factors' in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ('SEC'), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements. Contact InformationPress & Media Investor Relations SOURCE: Moolec Science SA press release
